

SCHU-204.1 PFF/NDH (09902857)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Dürst, Matthias and Nees, Matthias
Serial No. : Continuation of 09/308,984
Filed : Herewith
For : DNA For Evaluating The Progression Potential of Cervical Lesions
Group Art Unit : 1642
Examiner : J. Hunt

February 19, 2002

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend this application as follows:

IN THE SPECIFICATION

Page 1, prior to line, add: RELATED APPLICATION This application is a continuation of
Serial No. 09/308/984, filed September 3, 1999, now US Patent--

line 1: change "DNA" to --nucleic acid molecules--

line 3: change "coded" to --encoded-- and "DNA" to --nucleic acid molecules--

line 5: change "DNA" to --nucleic acid molecules--

line 8: change "The invasive" to --Invasive--

line 14: change "higher" to --more severe--

line 29: change "discussed" to --known--

Page 2, line 15: change "of no significance" to --not useful--

line 17: change "progression" to --progressive--

lines 19-20: delete and replace by --This is the subject of the invention set forth in the disclosure which follows.--

line 22: change "a" to --an isolated-- after "acid" add --molecule--; change "progression" to --progressive--

line 23: after "acid" add --molecule--

line 24: change "provided" to --obtained--; change "favorable" to --preferred--

line 26: change "for" to --of--

line 33: change "to do" to --of doing--

line 34: change "can be" to --are--

Page 3, line 5: change "can be" to --are--

line 13: delete "a"

line 14: change "is called" to --are known as--

line 15: change "anchorage" to --anchor--

line 17: change "calculated" to --known--

line 19: delete "an"

line 22: change "anchorage" to --anchor--

line 23: delete "a"

line 28: change "above" to --round of--

line 30: change "sequence" to --sequences--

lines 36-37: delete and replace by

--Both cDNA and RNA are examples of nucleic acid molecules in accordance with the invention, with cDNA--

Page 4, line 9: after "acid" add --molecule--

line 12: change "and" to --or an--

line 14: change "are" to --include--

line 21: change "to" to --which--

line 22: delete "a"

Page 5, line 6: change "subject matter" to --feature--

line 7: change "An above polypeptide" to --A polypeptide in accordance with the invention--

line 10: change "subject matter" to --aspect--

line 13: change "and" to --an--

line 24: change "progression" to --progressive--

line 34: after "acid" add --molecule--; delete second "a"

Page 6, line 1: change "as usual" to --in accordance with known methods--

line 3: change "statement on" to --diagnosis of--

lines 5-6: change "suitable to take steps against the" to --useful for preventing--

line 9: after "acid" add --molecule--

line 10: delete "a"

line 11: after "acid" add --molecule--

line 12: change "expression inhibition" to --inhibition of expression--

line 17: change "acids" to --acid molecules--

line 19: change "acids" to --acid molecules--

line 23: change "below examples" to --examples which follow--

Page 7, line 6: delete "(see above)"

lines 7-8: delete "the RQ1 RNase-free DNase of PROMEGA having been used" and replace by --using commercially available, RNase-free DNase purchased from PROMEGA--

line 9: delete "a"

line 10: delete "method"

lines 10-11: delete "what is called anchoring primers having been used as primers" and replace by --using anchor primers, as are described supra--

Page 8, line 1: change ", ultimately" to --Ultimately,--

Page 9, line 7: change "comparison of" to --comparing--

Page 10, line 3: change "determined" to --sequenced--

line 4: delete "as regards their sequence"

line 15: change "It showed" to --The results indicated--

next to last line: delete "a"

IN THE CLAIMS

Amend claims 3, 4, 5, 8, 10 & 12 as follows:

Claim 3, line 1: delete "or 2".

Claim 4, line 1: delete "or 2"

Claim 5, line 2: delete "or 2"

Claim 12 (amended): Kit comprising at least one [or several] nucleic acid[s] molecule according to claim 1, [polypeptides according to claim 5 or 6 and/or antibodies according to claim 8] and (s well as) a conventional auxiliary agent[s].

Claim 13: Kit comprising at least one polypeptide according to claim 5, and a conventional auxiliary agent.

Claim 14: Kit comprising at least one antibody according to claim 8, and a conventional auxiliary agent.


REMARKS

Entry of the foregoing amendment is requested. Claims 1-14 will be pending.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By



Norman D. Hanson

Reg. No. 30,946

666 Fifth Avenue
New York, New York 10103
(212) 318-3000